Search alternatives:
ns decrease » _ decrease (Expand Search), we decrease (Expand Search), use decreased (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
ns decrease » _ decrease (Expand Search), we decrease (Expand Search), use decreased (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
421
-
422
-
423
-
424
-
425
-
426
-
427
-
428
-
429
-
430
-
431
-
432
The <i>P[syt<sup>P-L</sup>]</i> mutation decreases the Ca<sup>2+</sup> affinity of release and vesicular release probability, but the readily releasable pool is unchanged.
Published 2017“…<p>(A) Mean EJP amplitudes from <i>+/-;P[syt<sup>WT</sup>]/+</i> (filled black circles) and <i>+/-;P[syt<sup>P-L</sup>]/+</i> (filled red circles) larvae at Ca<sup>2+</sup> levels ranging from 0.05 mM—5.0 mM. …”
-
433
-
434
-
435
-
436
-
437
Fenretinide decreases levels of PAX3/FOXO1 and its target genes in aRMS cell lines.
Published 2013“…D) Fenretinide did not decrease mRNA levels of FOXO1 in aRMS cells. qRT–PCR was carried out after treatment with an IC<sub>50</sub> concentration of fenretinide during different time points (24–48–72 hours). …”
-
438
-
439
-
440
Pre-treatment with CDDO-Me decreases IR-induced DNA damage in a variety of non-cancerous cells.
Published 2014“…(A) HBEC 3KT, (B) HME1, and (C) PBMCs were treated with CDDO-Me 18 hours prior to IR, then mounted on slides 30 min post-IR. …”